îæ€çŽ¢
îæ€çŽ¢
î
Pelthos Therapeutics Ord Shs
PTHSîãŠã©ãããªã¹ãã«è¿œå
26.720USD
-1.225-4.42%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
92.87Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± äŒæ¥å
Pelthos Therapeutics Ord Shsã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒã- -
äŒç€Ÿå- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°- -
蚌åžçš®é¡- -
決ç®ææ«- -
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæ- -
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒã- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -
Pelthos Therapeutics Ord Shsã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Ezra M. Friedberg
Mr. Ezra M. Friedberg
Independent Director
Independent Director
64.08K
-0.87%
Mr. Sai Rangarao
Mr. Sai Rangarao
Chief Commercial Officer
Chief Commercial Officer
30.52K
--
Dr. Richard Malamut
Dr. Richard Malamut
Independent Director
Independent Director
10.52K
-5.61%
Mr. Richard Baxter
Mr. Richard Baxter
Independent Director
Independent Director
3.19K
-499.94%
Mr. Francis P. (Frank) Knuettel, II
Mr. Francis P. (Frank) Knuettel, II
Chief Financial Officer, Treasurer, Company Secretary
Chief Financial Officer, Treasurer, Company Secretary
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Peter Greenleaf
Mr. Peter Greenleaf
Chairman of the Board
Chairman of the Board
--
--
Mr. Matthew Pauls
Mr. Matthew Pauls
Independent Director
Independent Director
--
--
Mr. Scott Plesha
Mr. Scott Plesha
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Ezra M. Friedberg
Mr. Ezra M. Friedberg
Independent Director
Independent Director
64.08K
-0.87%
Mr. Sai Rangarao
Mr. Sai Rangarao
Chief Commercial Officer
Chief Commercial Officer
30.52K
--
Dr. Richard Malamut
Dr. Richard Malamut
Independent Director
Independent Director
10.52K
-5.61%
Mr. Richard Baxter
Mr. Richard Baxter
Independent Director
Independent Director
3.19K
-499.94%
Mr. Francis P. (Frank) Knuettel, II
Mr. Francis P. (Frank) Knuettel, II
Chief Financial Officer, Treasurer, Company Secretary
Chief Financial Officer, Treasurer, Company Secretary
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sun, May 10
æŽæ°æå»: Sun, May 10
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Ligand Pharmaceuticals Inc
44.70%
Murchinson Ltd.
8.34%
Ikarian Capital LLC
7.62%
3I Management LLC
6.36%
Vanguard Capital Management, LLC
2.77%
ä»ã®
30.19%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Ligand Pharmaceuticals Inc
44.70%
Murchinson Ltd.
8.34%
Ikarian Capital LLC
7.62%
3I Management LLC
6.36%
Vanguard Capital Management, LLC
2.77%
ä»ã®
30.19%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
48.34%
Investment Advisor/Hedge Fund
17.52%
Hedge Fund
11.77%
Individual Investor
7.78%
Investment Advisor
4.19%
Private Equity
0.24%
ä»ã®
10.15%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Apr 1
æŽæ°æå»: Wed, Apr 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2026Q4
20
762.76K
10.36%
--
2026Q1
30
1.21M
35.96%
+404.95K
2025Q4
23
771.24K
24.99%
+360.35K
2025Q3
23
762.76K
24.89%
+686.23K
2025Q2
15
44.89K
7.45%
-74.71K
2025Q1
14
89.69K
14.94%
-16.15K
2024Q4
11
77.19K
12.98%
+14.42K
2024Q3
10
38.99K
6.70%
-15.38K
2024Q2
7
54.38K
9.43%
+29.19K
2024Q1
2
57.07K
9.90%
+57.07K
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Ligand Pharmaceuticals Inc
1.50M
44.7%
--
--
Nov 24, 2025
Murchinson Ltd.
289.48K
8.63%
+9.48K
+3.39%
Dec 31, 2025
Ikarian Capital LLC
255.76K
7.62%
+193.31K
+309.53%
Dec 31, 2025
3I Management LLC
213.51K
6.36%
-86.49K
-28.83%
Dec 31, 2025
Balmoral Financial Group LLC
92.07K
2.74%
--
--
Nov 24, 2025
Boothbay Fund Management, LLC
80.68K
2.4%
+59.44K
+279.76%
Dec 31, 2025
J. Goldman & Co., L.P.
78.01K
2.32%
+78.01K
--
Dec 31, 2025
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 27, 2025
Merger
10â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 27, 2025
Merger
10â1
